Regulus Therapeutics News

Buy Rating Affirmed for Regulus Therapeutics Amid Positive Clinical Advances for RGLS8429

TipRanksMay 10 18:46

Regulus Therapeutics Q1 2024 GAAP EPS $(0.29) Misses $(0.22) Estimate

Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.22) by 31.82 percent.

BenzingaMay 10 05:36

Regulus Therapeutics | 10-Q: Quarterly report

Futu NewsMay 10 04:32 · Announcements

Regulus Therapeutics 1Q Loss $8.47M >RGLS

Regulus Therapeutics 1Q Loss $8.47M >RGLS

Dow JonesMay 10 04:05

Press Release: Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates

Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates PR Newswire SAN DIEGO, May 9, 2024 Initiated the fourth cohort of patients in the Phase 1b multiple-ascending do

Dow JonesMay 10 04:05

HC Wainwright & Co. : Reiterated Regulus Therapeutics (RGLS.US) rating, adjusted from buy to buy rating, target price of $9.00.

HC Wainwright & Co. : Reiterated Regulus Therapeutics (RGLS.US) rating, adjusted from buy to buy rating, target price of $9.00.

Zhitong FinanceMay 7 02:10

Optimistic Buy Rating for Regulus Therapeutics' RGLS8429 Amid Promising ADPKD Treatment Progress

TipRanksMay 6 23:45

Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PRNewswireMay 6 20:00

Earnings Week Ahead: Disney, Palantir, Shopify, Uber, Plug Power and More

Seeking AlphaMay 5 20:00

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series

SAN DIEGO, April 30, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (t

PR NewswireApr 30 20:00

Regulus Files to Sell 62.5M Shares of Common Stock for Holders

Seeking AlphaApr 10 05:06

Buy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development Milestones

TipRanksMar 25 18:26

Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements

Yahoo FinanceMar 23 17:33

Regulus Therapeutics Q4 EPS $(0.40) Misses $(0.39) Estimate

Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.39) by 2.56 percent. This is unchanged from the same period last ye

BenzingaMar 22 04:08

Regulus Therapeutics 4Q Loss $8.06M >RGLS

Regulus Therapeutics 4Q Loss $8.06M >RGLS

Dow JonesMar 22 04:05

Press Release: Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates PR Newswire SAN DIEGO, March 21, 2024 Positive topline data from the second cohort of patients in

Dow JonesMar 22 04:05

Canaccord Genuity Trims Price Target on Regulus Therapeutics to $11 From $12, Maintains Buy Rating

Regulus Therapeutics (RGLS) has an average outperform rating and price target range of $3 to $11, according to analysts polled by Capital IQ. Price: 2.23, Change: -0.13, Percent Change: -5.51

MT NewswiresMar 19 22:15

Regulus Therapeutics Is Maintained at Buy by Canaccord Genuity

Regulus Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow JonesMar 19 20:22

Regulus Therapeutics Price Target Cut to $11.00/Share From $12.00 by Canaccord Genuity

Regulus Therapeutics Price Target Cut to $11.00/Share From $12.00 by Canaccord Genuity

Dow JonesMar 19 20:22

Canaccord Genuity Maintains Buy on Regulus Therapeutics, Lowers Price Target to $11

Canaccord Genuity analyst Whitney Ijem maintains Regulus Therapeutics with a Buy and lowers the price target from $12 to $11.

Analyst UpgradesMar 19 20:12